Suven Life Sciences logo

Suven Life Sciences financials: balance sheet, profit and loss, cash flow

NSE: SUVENBSE: 530239Healthcare ServicesSmall Cap

Suven Life Sciences Limited · Face value ₹1 · Listed May 1995 on BSE, Oct 2003 on NSE
Last close ₹268.05up ₹6.65 (2.54%)BSE ₹268.65

Share price at the NSE close on 28 Oct 2026. Previous close ₹261.40.

28 Oct: open ₹261.40, high ₹273.00, low ₹259.80

52-week range of traded prices to 28 Oct 2026
₹124.11Low, 24 Mar 2026₹403.35High, 1 Sep 2026
Market cap
₹7,574 Cr806th largest listed
P/E
Lossover the last 12 months
P/B
Shares changed
Dividend yield
Nonein the last 12 months
ROE
−100.5%
ROCE
−63.0%
Debt to equity
0.00
Volume, NSE
4,88,72142.2% delivered

Suven Life Sciences' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.Suven Life Sciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
54487Mar 17625124Mar 186648737Mar 1914−941.1Mar 2013−720.4Mar 2112−1220.5Mar 2214−1180Mar 2312−1050Mar 246.7−1610Mar 257.1−2760Mar 26
A loss in 7 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin
31.7%−3,998.8%23.7%31.7%24.2%−802.8%−594.0%−1,033.3%−929.8%−1,094.7%−2,490.7%−3,998.8%16.0%19.8%13.1%−653.6%−535.3%−1,030.0%−873.5%−898.6%−2,415.1%−3,884.1%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out.

The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹14 Cr, differs from its quarters added, ₹485 Cr.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue7.1
  2. Employee costs−24
  3. Other expenses−267
  4. Operating profit−285
  5. Depreciation−5.6
  6. Other income+14
  7. One-off items0.0
  8. Finance costs−0.2
  9. Profit before tax−276
  10. Tax0.0
  11. Net profit−276

What the company owns

  • Cash and bank₹337 Cr
  • Plant, investments and other assets₹285 Cr
  • Receivables₹2 Cr
  • Inventory₹0 Cr

What pays for it: net worth and liabilities

  • Net worth₹591 Cr
  • Other liabilities₹28 Cr
  • Owed to suppliers₹5 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Suven Life Sciences quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026Twelve monthsFiled 6 Aug
Revenue from operations5446256641413121412779
41542750313094134139140172292375
Materials and goods bought15215417400000000
Employee costs––661719211919212425
Other expenses––26311375113121121152267350
Operating profit before depreciation129198160−116−80−122−126−128−166−285−366
Operating margin23.7%31.7%24.2%−802.8%−594.0%−1,033.3%−929.8%−1,094.7%−2,490.7%−3,998.8%−4,155.5%
Materials, % of revenue––26.2%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Employee costs, % of revenue––10.0%120.8%137.5%177.5%137.5%162.4%312.9%339.4%288.8%
Other expenses, % of revenue––39.7%782.0%556.6%955.8%892.2%1,032.3%2,277.8%3,759.4%3,966.7%
Depreciation and amortisation21212244477666
Operating profit after depreciation108177138−120−84−127−132−135−172−290−373
Other income2123241485821111421
Finance costs65411100001
Profit before one-off items and tax123196159−106−77−122−124−114−161−276−352
One-off items00000067000
Profit before tax123196159−106−77−122−118−106−161−276−352
07272−12−500−1000
Net profit8712487−94−72−122−118−105−161−276−352
Other comprehensive income––000000−1−1−1
Total comprehensive income––87−95−72−122−118−105−161−278−354
Net margin16.0%19.8%13.1%−653.6%−535.3%−1,030.0%−873.5%−898.6%−2,415.1%−3,884.1%−3,998.7%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017 and Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
83114310896375270110591
Share capital1313131522222226
Reserves818131958235424888565
371000000
1492716811142331
5912542122
Total assets1,039182128108389285135624
4161162641137286078
623661036725225775547
Net debt−206−14−46−50−231−240−60−337
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
−133−128−208−83−154−302
−125−126−205−89−155−301
−52−4−93710−18
Receivables100000
Inventories000−100
Payables−3−1003−1
Other working capital−49−4−9386−18
Tax paid−1−1−161−1
Capital spending62032375
Free cash flow−139−147−211−85−191−307
93−22−15662155−462
35146396−1−1757
Dividends paid000000
Shares bought back000000
Shares issued014839700757
Net change in cash−5−432−220−7
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Suven Life Sciences dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Earnings per share₹6.84₹9.70₹6.83–−₹5.67−₹9.57−₹6.63−₹4.82−₹7.37−₹12.13
Diluted earnings per share₹6.84₹9.70₹6.83–−₹5.67−₹9.57−₹6.63−₹4.82−₹7.37−₹12.13
Dividend per share₹1.00₹1.50₹1.50–––––––
Book value per share––₹65.29₹11.26₹8.49₹6.61₹17.21₹12.38₹5.04₹22.43
Dividend payout14.6%15.4%22.0%–––––––
Shareholder yield––––0.0%−11.0%−37.6%0.0%0.0%−21.8%
Market cap at the year end (₹ crore)2,1052,1313,3212728991,3481,0582,1812,4793,473
Earnings per share is left blank for the year to Mar 2020: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Consolidated, years to March.Suven Life Sciences PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue growth9.0%14.8%6.1%–−6.5%−12.1%14.3%−13.6%−43.1%6.9%
Operating profit growth35.8%53.5%−19.1%–––––––
Net profit growth30.6%41.9%−29.7%–––––––
Earnings per share growth–41.8%−29.6%–––––––
––10.5%−19.3%−57.4%−119.5%−50.2%−32.6%−84.6%−78.8%
–––−29.8 pts−38.1 pts−62.1 pts69.3 pts17.6 pts−52.0 pts5.8 pts
From the net margin–––−532.3 pts3.5 pts−53.1 pts18.2 pts−1.4 pts−55.0 pts−51.5 pts
From asset turnover–––502.6 pts−42.4 pts−16.9 pts46.2 pts18.7 pts7.6 pts55.6 pts
From borrowing–––0.0 pts0.8 pts7.9 pts5.0 pts0.3 pts−4.7 pts1.7 pts
Return on capital employed––15.9%−83.0%−77.9%−131.2%−35.3%−49.8%−156.0%−49.1%
Interest cover18.938.236.6–––––––
Debt to equity––0.040.010.000.010.000.000.000.00
Receivable days––8357484022407377
Inventory days––330–––––––
Payable days––128–––––––
Cash conversion cycle, days––285–––––––
Working capital days––1466161,084249265101−4409,150
Asset turnover––0.640.020.090.100.050.030.030.02
Assets per rupee of net worth––1.251.251.231.161.051.041.111.08
Sales per rupee of plant––2.280.700.760.340.380.430.110.13
Capital spending to depreciation––––1.454.500.440.376.400.91
Plant being built, % of plant in use––38.2%–26.9%10.1%0.0%0.0%0.0%6.5%
Interest cover is left blank for the years to Mar 2020, Mar 2021, Mar 2022, Mar 2023, Mar 2024, Mar 2025 and Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. Revenue growth is left blank for the year to Mar 2020: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−72.8%
Measure10 years5 years3 years
Revenue growth, yearly rate–−12.0%−19.3%
Return on equity, average–−73.1%−65.3%
Return on capital employed, average–−84.3%−85.0%
Operating margin, average−1,086.5%−1,909.5%−2,528.1%
Net margin, average−1,024.1%−1,820.3%−2,399.3%
Asset turnover, average–0.050.03
Debt to equity, average–0.000.00

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−874−539−302
Cash from investing−424−246−462
Cash from financing1,297755757
Capital spending67455
Dividends paid000
Shares bought back000
Shares issued for cash1,302757757
Borrowings raised000
Borrowings repaid100

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––432322
Altman Z-scorePublished threshold 1.81––12.393.6626.4266.1247.7489.1056.5664.32
Beneish M-scorePublished threshold −1.78––––−0.77−2.42−0.11−2.86−3.405.53
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−20.6023.4998.75−24.95−76.93128.41
Receivables growth less revenue growthOur threshold 0 percentage points–––−0.66−15.90−14.21−52.1072.9147.005.98
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––0.00––––––
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−455.9344.7216.8641.13−46.14−13.082,723.22
Assets under construction, years of additionsOur threshold 2 years of additions––––3.290.160.00–0.001.95
Effective tax ratePublished threshold 17.16 per cent0.0036.7445.23–––––––
A threshold marked as ours has no published figure; it is the line we read the check against.